Mobile Platform for Optimizing Wellness and Engagement in Recovery

Summary

This pilot study addresses the urgent public health crisis of co-occurring opioid and alcohol use disorders (OUD-AUD), leading causes of mortality in the United States, by testing a scalable digital contingency management (CM) treatment among Medicaid beneficiaries. The study aims to evaluate the feasibility and acceptability of digital CM for OUD-AUD recovery, while also planning for broader implementation.

Conditions

• Opioid Agonist Treatment
• Alcohol Use Disorder
• Opioid Use Disorder

Interventions

BEHAVIORAL

Digital Contingency Management Intervention Arm

Participants will use a version of the app for 6-months. Participants in this group may earn rewards for completing recovery-related activities and for abstinence from drugs and alcohol. During the 6 months this will include: random saliva drug tests, breathalyzer tests, and video selfies, completing surveys and questionnaires through the app, and receiving rewards on a debit card for abstinent tests, surveys, and activities. Additionally, participants will complete follow-up at approximately 9 months after randomization.

BEHAVIORAL

Digital Wellness Arm

Participants will use a version of the app for 6-months focussed on wellness. During the 6 months this will include: random requests to do saliva drug tests, breathalyzer tests, and video selfies, complete surveys and questionnaires through the app, and receive rewards on a debit card for completing tests, surveys, and activities. Participants in this group may also earn rewards for completing study activities like tests and surveys. Additionally, participants will complete follow-up at approximately 9 months after randomization.

Sponsors & Collaborators

• National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  collaborator NIH

• DynamiCare Health

  collaborator INDUSTRY

• University of Michigan

  lead OTHER

Principal Investigators

• Lara Coughlin, PhD · University of Michigan

• Anne C Fernandez, PhD · University of Michigan

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

19 Years

Max Age

63 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-12-08

Primary Completion

2027-07-01

Completion

2027-07-31

Countries

• United States

Study Locations